STOCK TITAN
  1. Home
  2. News
  3. SEEL

Seelos Therapeutics Inc - SEEL STOCK NEWS

Welcome to our dedicated news page for Seelos Therapeutics (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on Seelos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seelos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seelos Therapeutics's position in the market.

News
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Rhea-AI Summary
Seelos Therapeutics, Inc. provided an update on the Phase 2/3 HEALEY ALS Platform trial, evaluating SLS-005 for ALS. While not meeting statistical significance overall, a pre-specified subgroup showed promising results. Seelos plans to discuss next steps with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.35%
Tags
none
-
News
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has entered into definitive agreements for the purchase and sale of 3,404,256 shares of its common stock in a registered direct offering and unregistered common warrants. The offering is priced at $1.175 per share, with accompanying common warrants exercisable for up to an aggregate of 3,404,256 shares of common stock. The common warrants will have an exercise price of $1.05 per share and will expire 5 years from the initial exercise date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
offering
-
News
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) plans to continue potential partnership discussions and proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk of Suicide. The FDA agreed that the primary endpoint in a Phase III trial could be the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 16, giving Seelos further confidence for its Phase III development of SLS-002.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
clinical trial
News
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) released an update letter to stockholders from CEO Raj Mehra, discussing the reverse stock split, underwritten public offering, and the progress of their lead programs SLS-002 and SLS-005. The company is encouraged by the selection of SLS-002 for a U.S. Department of Defense trial and is working closely with the DOD for the study. They also completed an End of Phase II meeting with the FDA for SLS-002 and are working on Phase II/III study in ALS for SLS-005. However, there are concerns about the financial constraints affecting the Phase IIb/III study in Spinocerebellar Ataxia, which was temporarily paused. The company is also seeking approval for proposals related to increasing the number of authorized shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
News
Seelos Therapeutics Announces Closing of Public Offering
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) closed an underwritten public offering of 1,781,934 shares of common stock, pre-funded warrants to purchase up to 2,422,612 shares of common stock, and accompanying common warrants to purchase up to 4,204,546 shares of common stock. The net proceeds are expected to be approximately $5.0 million, which will be used for general corporate purposes, product development, and to make periodic payments under or repay a portion of outstanding convertible promissory note issued in November 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has priced its underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock, and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. The gross proceeds from the offering are anticipated to be approximately $5.55 million, with the net proceeds intended for general corporate purposes, product development, and debt repayment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-47.48%
Tags
offering
News
Seelos Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has announced the commencement of an underwritten public offering of shares of its common stock and accompanying common warrants, with the intention to grant the underwriters a 45-day option to purchase additional shares. The offering is subject to market conditions and is being made pursuant to an effective 'shelf' registration statement on Form S-3. The company will use the proceeds from the offering for general corporate purposes and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-47.48%
Tags
offering
-
News
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
Rhea-AI Summary
Seelos Therapeutics, Inc. (SEEL) announces that SLS-002 has been selected for an adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD) in active-duty service members and veterans. The trial, funded by the U.S. Department of Defense's Defense Health Agency, will evaluate the safety, tolerability, and efficacy of multiple pharmacotherapeutic interventions. Seelos is optimistic about the potential of SLS-002 to address the significant unmet medical need in treating PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2421.01%
Tags
none
-
News
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
Rhea-AI Summary
Seelos Therapeutics, Inc. (SEEL) announced a 1-for-30 reverse stock split to regain compliance with the Nasdaq's minimum bid price requirement of $1.00 per share. The reverse stock split will reduce the number of issued and outstanding shares from approximately 167.7 million to approximately 5.6 million, with the new CUSIP number 81577F208.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23%
Tags
none
News
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
Rhea-AI Summary
Seelos Therapeutics has been selected to present a poster on the study of SLS-005 in a tauopathy model of Alzheimer's disease at the Neuroscience 2023 meeting. The preliminary analysis showed a 46% reduction in tau protein and an 18% reduction in NfL protein biomarker after 6 months of SLS-005 administration. SLS-005 has previously demonstrated an efficacious reduction of mHTT, the mutant protein implicated in Huntington's disease, by 77% in striatum and 84% in cortex.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock SEEL logo
Seelos Therapeutics Inc

Nasdaq:SEEL

SEEL Rankings

N/A Ranked by Market Cap
#5248 Ranked by Stock Gains
N/A Ranked by Dividends

SEEL Stock Data

6.32M
13.40M
2%
21.66%
5.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About SEEL

seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a